Science for a Better Life

BMO Farm to Market Conference

May 14, 2020
Liam Condon,
President of the Crop Science Division
Forward-Looking Statements

This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management.

Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at http://www.bayer.com/.

The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Agenda

Bayer Group Overview

Vision and Strategic Pillars for Crop Science
We address megatrends that impact lives across the globe

### Megatrends through 2050

#### Aging population

<table>
<thead>
<tr>
<th>Age 60+</th>
<th>2017</th>
<th>2050</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growth</td>
<td>1.0</td>
<td>2.1</td>
</tr>
</tbody>
</table>

- >100% of total population\(^1\)

#### Growing population

<table>
<thead>
<tr>
<th>People, in bn</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
</tr>
<tr>
<td>2050</td>
</tr>
</tbody>
</table>

- +2.2bn people\(^1\)

#### Pressure on ecosystems

<table>
<thead>
<tr>
<th>Area, in m²</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
</tr>
<tr>
<td>2050</td>
</tr>
</tbody>
</table>

- -20% Significant loss in arable land per capita\(^3\)

---

\(^1\) World Population Prospects: The 2017 Revision

\(^2\) FAO 2017, (FAO Global Perspective Studies)


\(^4\) Nelson et. al, (2014); FAO 2016 “Climate change and food security”
This is the hour of science; health and nutrition are essential.

As the globe addresses the COVID-19 pandemic, the basic supply of health and nutrition has never been more relevant and the role of science in providing solutions, never more pressing.
We are a global leader in health and nutrition

Our vision: health for all...... hunger for none

Our purpose: Science for a Better Life

Use natural resources more efficiently & responsibly

Secure sufficient supply of quality food

Preserve & restore health
We are well positioned in attractive markets

- **Crop Science**: €19.8bn, #1 Position
- **Pharmaceuticals**: Approximately €880 bn
- **Consumer Health**: Approximately €140 bn

**Global Sales FY 2019**
- €43.5bn

1. 2019 market size
2. Source: Bayer CS market model (CP, Seed & ES) – March 2020
3. Source: IQVIA 2019 – 955bn USD, 1.08 translation rate
Innovation, sustainability and operational excellence intersect to drive value creation

Through our leading positions in Health & Nutrition we create value for our shareholders and society

What We Do

Our Value Levers Are Designed to Deliver Attractive Returns

World-class innovation

Operational excellence

Disciplined capital allocation

Highest sustainability standards
In 2019 we delivered on our commitments

Operational targets achieved:
Sales and earnings increased

Strategic targets achieved:
All the announced portfolio measures implemented or agreed upon

Efficiency targets achieved:
Savings and synergies ahead of budget

Ambitious sustainability targets set and anchored

Record investment in research and development
2020: Good start to the year; COVID-19 influences outlook and priorities for the remainder

1. Employee Health
   - Securing health and safety of employees

2. Business Continuity
   - Safeguarding supply, production, logistics and business operations

3. Humanitarian Efforts
   - Health for all, hunger for none – using our expertise in health and nutrition in global crisis
Focus areas 2020

1. **Group**
   - Maintain operational targets; adapt as necessary from COVID-19
   - Continued focus on cash flow

2. **Crop Science**
   - Continue with integration
   - Focus on pipeline execution

3. **Pharmaceuticals**
   - Progress with pipeline developments, launch new indications / products

4. **Consumer Health**
   - Continue to drive growth acceleration program

5. **Efficiency / Bayer 2022**
   - Follow through with efficiency improvement program and realize synergies

6. **Portfolio Measures**
   - Closing of Animal Health sale, expected by mid 2020
Agenda

Bayer Group Overview

Vision and Strategic Pillars for Crop Science
We seek to deliver world-class innovation, new standards in sustainability and pioneer a digital transformation in agriculture to feed a growing global population.

Shaping agriculture to benefit farmers, consumers and our planet

As the industry leader uniquely positioned to create value through innovative tailored solutions
Four core pillars underpin our vision for Crop Science

1. Drive operational excellence
2. Deliver world-class innovation
3. Pioneer the Digital Transformation
4. Set New Standards in Sustainability
Integration and synergies ahead of plan in Crop Science

**Integration Achievements**

// Crop Science functions advancing rapidly with **organizational integration**; selections essentially complete

// Support functions to be completed in alignment with Bayer 2022 project

// **Cultural Integration**: Continued high levels of employee engagement; ~75%

// **Cost Synergies**:

// Now expect ~70% of the synergy target complete by end of 2020 vs. original target of 55%

// Focused on headcount, IT and infrastructure savings

**Cost Synergies**: ~€870m (~$1bn) as of 2022

<table>
<thead>
<tr>
<th>Year</th>
<th>H2 2018</th>
<th>2019</th>
<th>2020e</th>
<th>2021e</th>
<th>2022e</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual Cost Synergies</td>
<td>-5%</td>
<td>&gt;40%</td>
<td>-70%</td>
<td>-80%</td>
<td>100%</td>
</tr>
</tbody>
</table>

**Sales Synergies**: ~€170m (~$200m) as of 2022

// **Four countries** to generate >60% of the sales synergies

// U.S.A., Brazil, Argentina and Mexico

// Bayer Plus program generating incremental sales in the U.S. in first season

---

1 Net EBITDA impact before special items, net of estimated dissynergies such as termination of selected distribution agreements as well as sales disruptions

2 Majority of one-time costs to achieve synergies expected to be recorded as special items

Applied FX rate of USD/EUR of 1.15
Unmatched R&D investment powers industry-leading profitability

#1 R&D Platform in Crop Science

- >7,800 R&D employees\(^2\) in >50 countries
- >20 large-scale R&D centers
- Partner of choice
- Technology provider to the industry

### Bayer Crop Science

#### Ag R&D Expense (€bn)\(^1\)

- Bayer Crop Science: 2.3
- Corteva: 1.0
- Syngenta Group: 0.9
- BASF Ag: 0.9

\(^1\) Bayer and Corteva based on 2019 reported R&D and there is an internal proforma estimate derived from company reports for the newly formed Syngenta Group. Proforma estimate for the SYT group includes the 2019 reported R&D expense for Syngenta – not including capitalized R&D of $344M to be comparable to peers in the chart. The Syngenta Group estimate does not consider Sinochem R&D. BASF is based on 2018 reported R&D expense.

\(^2\) Includes permanent and temporary employees
Advancing agriculture with a decade of transformative products

Key product highlights featured represent >€22bn\(^3\) of peak sales potential

### Select Planned Product Launches\(^1\)

<table>
<thead>
<tr>
<th>Herbicides</th>
<th>Expected Ongoing Refreshment</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
<th>2025</th>
<th>2026</th>
<th>2027</th>
<th>2028</th>
<th>2029</th>
<th>2030</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Formulation Launches in the next Decade</td>
<td>· New Soybean Selective Herbicide Mixtures</td>
<td>· New Non-Selective PPO Herbicide(^2)</td>
<td>· New Mode of Action Herbicide</td>
<td>· New Autumn Herbicides for Cereals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corn</td>
<td>150+ New Hybrids Commercialized Annually</td>
<td>FieldView Advanced Seed Scripting</td>
<td>· 3(^{rd}), 4(^{th}) and 5(^{th}) Generation Herbicide Tolerance Traits</td>
<td>· Short Stature Corn Hybrids/Short Stature Corn Trait</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soybeans</td>
<td>150+ New Varieties Commercialized Annually</td>
<td>FieldView Seed Placement</td>
<td>· 4(^{th}) and 5(^{th}) Generation Herbicide Tolerance Traits</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fungicides</td>
<td>20+ New Formulation Launches in the next Decade</td>
<td>Fox Supra (Indiflin(^®)) for Soybeans(^2)</td>
<td>· New Fungicide for Asian Soybean Rust</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insecticides</td>
<td>20+ New Formulation Launches in the next Decade</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other, Vegetables, Environmental Science, Seed Growth</td>
<td>~150 Vegetable Hybrids/Varieties Commercialized Annually</td>
<td>3(^{rd}) Gen BioRise Microbial Seed Treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>20+ New Formulation Launches in the next Decade</td>
<td>Lygus &amp; Thrips Control Cotton Trait</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 Subject to regulatory approvals and pending registrations. Represents a subset of the pipeline. Launches are all approximates.

2 In collaboration with Sumitomo.

3 Internal estimate; ~45% of the peak sales potential is incremental
FieldView: the leading brand and digital platform for growers

Growth Fueled by Platform Advantages

- **110m Acres**
  Subscribed acre target for 2020

- **#1 Brand**
  in digital Ag space

- **Largest Database**
  of grower and field trial seed performance data in the industry

- **New Business Models**
  enabling sharing of value and risk

- **~1bn Global Acre**
  Opportunity for Corn, Soybean, Wheat

- **>70 Partners**
  on the FieldView Platform

- **>35 Next-Gen Projects**
  in the pipeline

Data Collection Accelerating

- **32**
  Months to Collect 10m Connected Hours

  - **First 10m Hours**
  - **Second 10m Hours**

  **FieldView Drive**
  Connected combines, planters and sprayers uploading data to complement our R&D data to inform, improve models & tools

- **9**

---

1 Internal estimates
2 2018 Brand Health Monitor
3 Harvested acres – USDA FAS 2018-10-11, ex China
**Enhancing sustainability and biodiversity in agriculture**

Bayer’s Sustainability Commitments by 2030

<table>
<thead>
<tr>
<th>Advancing a carbon-zero future for agriculture</th>
<th>30% Reduction in field greenhouse gases emitted per kg of crops produced</th>
</tr>
</thead>
<tbody>
<tr>
<td>Produce higher-yielding crops with fewer natural resources and inputs</td>
<td>30% Reduction in impact on the environment</td>
</tr>
<tr>
<td>Empower 100 million smallholder farmers</td>
<td>100m Smallholders benefit e.g. from access to education, tailored solutions &amp; partners</td>
</tr>
</tbody>
</table>

- Climate-smart practices:
  - No-tillage
  - Highly Productive Crops
  - Cover Crops
  - Precision Agriculture
  - Optimize use of synthetic fertilizers through the use of microbes

- Climate FieldView for precision application of pesticides/fertilizers
- Resistant traits help to reduce pesticide use
- Develop crop protection products with lower environmental impact

- Enhancing social innovation (e.g. with Better Life Farming)
- Digital transformation with FarmRise
- Introduce new, higher-yielding, resource efficient rice hybrids

Produce higher-yielding crops with fewer natural resources and inputs. Empower 100 million smallholder farmers. Enhancing social innovation (e.g. with Better Life Farming). Digital transformation with FarmRise. Introduce new, higher-yielding, resource efficient rice hybrids.
Q&A Session

Liam Condon
President,
Crop Science Division

Robert Reiter, Ph. D.
Head of R&D,
Crop Science Division

Laura Meyer
Senior Manager,
Investor Relations
Q1 2020 financial results

Divisional summaries

Crop science pipeline highlights

Pharma pipeline highlights
2020: Good start to the year

Sales and earnings growth in all three divisions
- Sharp rise in demand for some consumer health products, e.g. nutritional supplements, and some increased stocking of crop protection due to COVID-19
- Limited negative impact from pandemic restrictions in certain parts of the business
- Strong increase of EBITDA before special items due to volume increases and cost synergies

<table>
<thead>
<tr>
<th></th>
<th>Q1’19</th>
<th>Q1’20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>12,252</td>
<td>12,845</td>
</tr>
<tr>
<td>Positive FX effect of €44 million</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Q1’19</th>
<th>Q1’20</th>
</tr>
</thead>
<tbody>
<tr>
<td>EBITDA*</td>
<td>3,983</td>
<td>4,391</td>
</tr>
<tr>
<td>Positive FX effect of €41 million</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\* In million €, before special items
Crop Science off to a good start

- 6% cpa sales growth, with contributions from all regions
- Good growth across insecticides, fungicides, corn seed & traits and herbicides
- Soybean seed & traits continue to decline due to competition
- Strong increase of EBITDA before special items due to volume increases and cost synergies

Sales

<table>
<thead>
<tr>
<th></th>
<th>Volume</th>
<th>Currency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1'19</td>
<td>+6%</td>
<td>+0%</td>
</tr>
<tr>
<td>Q1'20</td>
<td>+6%</td>
<td>+0%</td>
</tr>
</tbody>
</table>

EBITDA

<table>
<thead>
<tr>
<th></th>
<th>Price</th>
<th>Portfolio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1'19</td>
<td>+0%</td>
<td>0%</td>
</tr>
<tr>
<td>Q1'20</td>
<td>+14%</td>
<td>0%</td>
</tr>
</tbody>
</table>
Pharmaceuticals performance driven by Xarelto

- Xarelto (+19%) as main growth contributor
- Eylea (+1%) impacted by phasing
- China with softer growth partly due to phasing in anticipation of volume-based procurement introduction
- Solid increase in EBITDA before special items
- EU approval for darolutamide and pre-filled syringe for Eylea
- Positive phase III data for Vericiguat (VICTORIA) and Xarelto (VOYAGER PAD)
Strong demand for Consumer Health products in all regions

- All regions with elevated demand primarily related to the COVID-19 epidemic
- Strong growth across categories, especially in Nutritionals (+34%), Pain and Cardio (+20%) and Allergy & Cold (+15%)
- Margin expansion driven by sales growth offsetting negative portfolio effect and higher marketing expenses
- Positive effect on earnings by growth acceleration program (“Fit to Win”)
Outlook: Impact variables of COVID-19 situation

**Production and Supply**
- Stability of entire supply chain
- Inventory / Safety stock
- Logistics, also impact on costs

**Demand Dynamics**
- Demand patterns, e.g. stockpiling
- Impact on elective treatments
- Bio-fuel demand & seasonal labor
- Clinical trials and regulatory processes

**Financial Markets**
- Debt market access / interest rates
- Payment behavior of customers and solvency of suppliers
- FX volatility

**Trends / Opportunities**
- Cost management
- Acceleration of digitalization
- Role of science in society
Crop Science: number one global platform

Sales development
In €m

Sales by region
In %, in 2019

Leading product areas
In %, based on sales 2019

EBITDA margin development
In %, before special items ²

Market positions¹

Key products

¹ Source: Bayer CS market model ² 2019 cEBITDA restated for change in value flow concept

// BMO Farm to Market Conference // May 14, 2020
Pharma: focused on therapeutic areas with high unmet needs

**Sales development**
In €m

<table>
<thead>
<tr>
<th>Year</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>15,308</td>
<td>16,420</td>
<td>16,847</td>
<td>16,746</td>
<td>17,962</td>
</tr>
</tbody>
</table>

**EBITDA margin development**
In %, before special items

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>EBITDA margin</td>
<td>30.7</td>
<td>30.2</td>
<td>32.0</td>
<td>33.9</td>
<td>33.4</td>
<td>32.6</td>
<td>&gt;35.0</td>
</tr>
</tbody>
</table>

**Sales by region**
In %, in 2019

- North America: 22%
- Latin America: 34%
- Asia / Pacific: 39%
- EMEA: 5%

**Therapeutic areas**
In %, based on sales 2019

- Cardiovascular: 36%
- Hematology: 11%
- Ophthalmology: 16%
- Oncology: 10%
- Radiology: 8%
- Women’s Health: 5%
- Other: 14%

**Leading positions in key therapeutic areas**

- Cardiovascular
- Hematology
- Retinal Diseases
- Women’s Health
- Radiology

**Key products**
In €m

- Xarelto: 4,126
- Eyylea: 2,494
- Kypros: 418
- Xafigo: 411
- other: 303

---

1 Source: IQVIA 2017
2 2019 cEBITDA restated for change in value flow concept

© BMO Farm to Market Conference May 14, 2020
Consumer Health: focus on five core OTC categories

FINANCIALS

Sales development
In €m

<table>
<thead>
<tr>
<th>Year</th>
<th>Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>6,076</td>
</tr>
<tr>
<td>2016</td>
<td>6,037</td>
</tr>
<tr>
<td>2017</td>
<td>5,862</td>
</tr>
<tr>
<td>2018</td>
<td>5,450</td>
</tr>
<tr>
<td>2019</td>
<td>5,462</td>
</tr>
</tbody>
</table>

EBITDA margin development
In %, before special items

<table>
<thead>
<tr>
<th>Year</th>
<th>Margin</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>23.6</td>
</tr>
<tr>
<td>2015</td>
<td>24.0</td>
</tr>
<tr>
<td>2016</td>
<td>23.4</td>
</tr>
<tr>
<td>2017</td>
<td>21.0</td>
</tr>
<tr>
<td>2018</td>
<td>20.1</td>
</tr>
<tr>
<td>2019</td>
<td>20.9</td>
</tr>
<tr>
<td>2022E</td>
<td>&gt;24.0</td>
</tr>
</tbody>
</table>

Sales by region
In %, in 2019

- North America: 42%
- Latin America: 33%
- Asia / Pacific: 11%
- EMEA: 14%

PRODUCTS

Categories
In %, based on sales 2019

- Digestive Health: 23%
- Allergy & Cold: 17%
- Pain & Cardio: 15%
- Dermatology: 12%
- Nutritionals: 22%

Market positions

- #2: Nutritional
- #4: Pain & Cardio
- #5: Dermatology

Key products

- elevit
- Rennie
- Claritin
- Allize
- Coseptin
- Cebolan
- Afrin
- Iberogast
- Bepanthen

1 PARS database January 2019
2 2019 cEBITDA restated for change in value flow concept
Appendix

Q1 2020 financial results

Divisional summaries

Crop science pipeline highlights

Pharma pipeline highlights
Advanced Breeding Underpins Leadership in Corn Seed & Traits

Expect to Commercialize >150 Corn Hybrids a Year to Drive Growth in €5.2bn\textsuperscript{2} Corn Seed & Traits Sales

<table>
<thead>
<tr>
<th>Region</th>
<th>Avg. bu/ac advantage\textsuperscript{1}</th>
<th>Market Pos.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mexico</td>
<td>&gt;5</td>
<td>#1</td>
</tr>
<tr>
<td>Brazil</td>
<td>&gt;10</td>
<td>#1</td>
</tr>
<tr>
<td>Argentina</td>
<td>&gt;10</td>
<td>#1</td>
</tr>
<tr>
<td>United States</td>
<td>7–10</td>
<td>#1</td>
</tr>
<tr>
<td>Europe</td>
<td>3–4</td>
<td>#2</td>
</tr>
<tr>
<td>South Africa</td>
<td>&gt;5</td>
<td>#1</td>
</tr>
</tbody>
</table>

\textsuperscript{1} Range is either less than or inclusive of the current 3-year average yield advantage based on a comparison of yield data from new Bayer Crop Science products in their year of deployment against competitive market leaders for said region or country. Averages weighted in countries/regions by hybrid market size and exclude non-grain market.

\textsuperscript{2} 2019 proforma sales
XtendFlex Soybeans; Planting Production for 20M Acres in 2021

Built on the Proven Performance Roundup Ready 2 Xtend Soybeans

Provides exceptional weed control and yield with a triple-stack herbicide-tolerance trait providing growers with the flexibility of three over-the-top herbicide options:

- Glyphosate
- Low-Volatility Dicamba
- Glufosinate

- Increases spectrum of control from 350 to 375 weed species; Enlist E3™ system only controls 260
- Average 2019 yield and agronomic performance consistent with Roundup Ready 2 Xtend soybeans
- Planting stewarded production plan to enable 20M acres in the U.S. in 2021

1 Commercial availability pending regulatory approval
2 Based on EPA labels for the chemistries
3 Derived from 26 site locations in SC, NE, IN, IL, WI, MO, IN, AR, IA, NC, KS, SD, OH & GA

Xtendimax with VaporGrip Technology is a Restricted Use Pesticide. Always read and follow label instructions. Products not registered in all jurisdictions.
Enlist E3™ is trademark of Corteva

// BMO Farm to Market Conference /// May 14, 2020
Fox Xpro Fungicide Upgrades Fox Franchise in Brazil
Full Control of All Relevant Diseases in Soybeans; €600m Peak Sales Potential Opportunity

Builds on #1 position in soybean fungicides¹: >400% sales growth in 2019/20 season

/// Long-lasting solution to offer full control of all relevant soybean diseases including Asian Soybean Rust
/// Combines three different actives from different classes to provide excellent disease control and unmatched resistance management properties
/// AGROW Award 2019 “Best Formulation Innovation”: Optimized formulation to boost performance and minimize environmental impact by reducing off-target losses
/// Enables use in major crop rotation systems with cotton, corn, cereals and sunflower
/// Next-generation technology, Fox Supra (Indiflin®²), in Phase 4

¹ Internal estimates
² In collaboration with Sumitomo.
Always read and follow label instructions. Products not registered in all jurisdictions.

Reduces environmental impact through innovative formulation

Industry Standard

Fox Xpro

/// BMO Farm to Market Conference /// May 14, 2020

34
Two Approaches to Short Stature Corn Advance

Genome Editing Reveals Promising Third Option

Three Development Approaches to Short Stature Corn Provide Options to Access Multiple Markets

// **Breeding: ADVANCED TO PHASE 3**
Advanced breeding used to introgress naturally occurring short stature characteristic into elite germplasm.

![VITALA commercial beta in Mexico in 2020](image)

// **Biotech: ADVANCED TO PHASE 3**
In collaboration with BASF, uses transgene to shorten internodes; enables applicability across wide-array of germplasm.

NEW! // **Genome Editing: DISCOVERY**
Multiple, elegant approaches to generate short-stature corn, creating potential for opportunities in multiple markets.
New Herbicide Molecule Unlocks Greater Flexibility
First New Post-Emergence Mode of Action for Broad Acre Weed Control in 30 Years

Potential to build on #1 position in global herbicides¹

// Entirely new mode of action advanced to Phase 2 early development
// Demonstrates effective control of key resistant grasses, including Goosegrass and Sourgrass
// Discovery program launched in biotechnology to discover a matching herbicide tolerant trait; initial approaches under evaluation

¹ Internal estimates

Enables continued use of conservation tillage and no-till systems which improve carbon sequestration and soil health
Appendix

- Q1 2020 financial results
- Divisional summaries
- Crop science pipeline highlights
- Pharma pipeline highlights
## Late-stage pipeline with progress in oncology

<table>
<thead>
<tr>
<th>Indication</th>
<th>Status</th>
<th>Commercial Potential</th>
<th>Clinical Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Larotrectinib (Vitrakvi)</td>
<td>TRK-fusion Cancer</td>
<td>Launched</td>
<td>PSP &gt;€750m</td>
</tr>
<tr>
<td>Darolutamide (Nubeqa)</td>
<td>Prostate Cancer</td>
<td>Launched (nmCRPC)</td>
<td>PSP &gt;€1bn</td>
</tr>
<tr>
<td>Copanlisib (Aliqopa)</td>
<td>Lymphoma</td>
<td>Launched in the US</td>
<td>PSP &gt;€0.5bn</td>
</tr>
<tr>
<td>Finerenone</td>
<td>Diabetic Kidney Disease</td>
<td>Phase III</td>
<td>PSP &gt;€1bn</td>
</tr>
<tr>
<td>Vericiguat</td>
<td>Chronic Heart Failure</td>
<td>Phase III (HFrEF)</td>
<td>PSP ~€0.5bn</td>
</tr>
</tbody>
</table>

**NTRK**: Neurotrophic receptor tyrosine kinase; **nmCRPC**: Non-metastatic castration resistant prostate cancer; **mHSPC**: Metastatic hormone sensitive prostate cancer; **HFrEF**: Heart failure with reduced ejection fraction; **HFpEF**: Heart failure with preserved ejection fraction; **PSP**: Peak sales potential

<table>
<thead>
<tr>
<th>Indication</th>
<th>Status</th>
<th>Commercial Potential</th>
<th>Clinical Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphoma</td>
<td>Launched in the US</td>
<td>PSP &gt;€0.5bn</td>
<td></td>
</tr>
<tr>
<td>Darolutamide (Nubeqa)</td>
<td>Prostate Cancer</td>
<td>Launched (nmCRPC)</td>
<td>PSP &gt;€1bn</td>
</tr>
<tr>
<td>Copanlisib (Aliqopa)</td>
<td>Lymphoma</td>
<td>Launched in the US</td>
<td>PSP &gt;€0.5bn</td>
</tr>
<tr>
<td>Finerenone</td>
<td>Diabetic Kidney Disease</td>
<td>Phase III</td>
<td>PSP &gt;€1bn</td>
</tr>
<tr>
<td>Vericiguat</td>
<td>Chronic Heart Failure</td>
<td>Phase III (HFrEF)</td>
<td>PSP ~€0.5bn</td>
</tr>
</tbody>
</table>

**Launched** in the US

**Completed**

**PSP**

---

NTRK: Neurotrophic receptor tyrosine kinase; nmCRPC: Non-metastatic castration resistant prostate cancer; mHSPC: Metastatic hormone sensitive prostate cancer; HFrEF: Heart failure with reduced ejection fraction; HFpEF: Heart failure with preserved ejection fraction; PSP: Peak sales potential